SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization
Key Highlights
- ➤Q3 revenue $2.19 million, up more than tenfold year over year
- ➤Net loss $1.595 million, down 55% from the prior-year quarter
- ➤Gross profit $1.362 million; gross margin increased to approximately 62%
- ➤$2.0 million raised from exercising 941,423 Class B warrants at $2.14
- ➤FDA-cleared SiNAPTIC Foot & Ankle System entered limited-use commercial release
Expert Statements
Eric Olson, Chief Executive Officer and Chairman of the Board of SINTX Technologies
“Our third-quarter results represent a meaningful milestone in the commercial transformation of SINTX Technologies”
Eric Olson, Chief Executive Officer and Chairman of the Board of SINTX Technologies
“The substantial increase in quarterly revenue, combined with significant improvements in gross profit and operating performance, demonstrates the potential of our advanced manufacturing platform as we convert investments over the past several years into revenue-building commercial opportunities.”
Eric Olson, Chief Executive Officer and Chairman of the Board of SINTX Technologies
“Our industrial business is providing an important commercial foundation as we pursue what we believe are even greater long-term opportunities in healthcare.”
Eric Olson, Chief Executive Officer and Chairman of the Board of SINTX Technologies
“With the initial commercial sales of our SiNAPTIC(®) Foot & Ankle Osteotomy Wedge System underway, we have established a foundation for expanding our presence in the orthopedic implant market.”
Eric Olson, Chief Executive Officer and Chairman of the Board of SINTX Technologies
“We also continue to evaluate opportunities to leverage our proprietary silicon nitride technology in spinal applications, next-generation orthopedic implants, advanced composites, and antipathogenic medical technologies such as wound care and wound dressing applications.”
Eric Olson, Chief Executive Officer and Chairman of the Board of SINTX Technologies
“We believe our performance this quarter demonstrates measurable progress toward building a commercially focused advanced materials company.”
Eric Olson, Chief Executive Officer and Chairman of the Board of SINTX Technologies
“With improving operating performance, expanding commercial activities, and continued investment in our proprietary technologies, we believe SINTX is well positioned to pursue additional growth opportunities in 2027.”
Third quarter revenue increases more than tenfold year over year, while operating losses decrease 51% as Company advances commercialization of its proprietary silicon nitride technologies
SALT LAKE CITY, Utah, Nov. 05, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a global leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today announced its financial results and business highlights for the third quarter ended September 30, 2026.
Get started
Create a free account to read the full story.